Marinus Pharmaceuticals, Inc. (61Y.F)
| Previous Close | 1.2100 |
| Open | 1.2000 |
| Bid | 1.1800 x N/A |
| Ask | 1.2900 x N/A |
| Day's Range | 1.2000 - 1.2000 |
| 52 Week Range | 1.1800 - 10.2000 |
| Volume | |
| Avg. Volume | 42 |
| Market Cap | 67.681M |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.4700 |
| Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.88 |
ZacksPTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Business WireMarinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus
RADNOR, Pa., June 17, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline results from the Phase 3 double-blind, randomized, placebo-controlled RAISE trial (NCT04391569) evaluating the safety and efficacy of intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE). RSE, in which prolonged continuous or rapidly recurring seizures do not r
ZacksAvidity (RNA) Up 33% on Rare Muscle Disease Study Results
Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
